Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Derazantinib Monotherapy and Combination in HER2-negative Gastric Cancer
NCT04604132Phase 2Terminated
- Sponsor
- Basilea Pharmaceutica
- Start
- Oct 2020
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 2 trial of derazantinib in gastric adenocarcinoma, sponsored by Basilea Pharmaceutica. Started Oct 2020; status: terminated.
02
Drugs
derazantinib
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT04604132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04604132.